Carisma Therapeutics Inc
NASDAQ:CARM

Watchlist Manager
Carisma Therapeutics Inc Logo
Carisma Therapeutics Inc
NASDAQ:CARM
Watchlist
Price: 0.186 USD 5.68% Market Closed
Market Cap: 7.8m USD

Intrinsic Value

CARM's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CARM stock under the Base Case scenario is 1.342 USD. Compared to the current market price of 0.186 USD, Carisma Therapeutics Inc is Undervalued by 86%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CARM Intrinsic Value
1.342 USD
Undervaluation 86%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Carisma Therapeutics Inc

Valuation History Unavailable

Historical valuation for CARM cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CARM?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Carisma Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Carisma Therapeutics Inc

Current Assets 14m
Cash & Short-Term Investments 7.7m
Receivables 1.2m
Other Current Assets 5m
Non-Current Assets 2m
PP&E 2m
Efficiency

Free Cash Flow Analysis
Carisma Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Carisma Therapeutics Inc

Revenue
20m USD
Operating Expenses
-72m USD
Operating Income
-52m USD
Other Expenses
1.2m USD
Net Income
-50.8m USD
Fundamental Scores

CARM Profitability Score
Profitability Due Diligence

Carisma Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional ROE
ROE is Increasing
Exceptional 1-Year Revenue Growth
40/100
Profitability
Score

Carisma Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

CARM Solvency Score
Solvency Due Diligence

Carisma Therapeutics Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
31/100
Solvency
Score

Carisma Therapeutics Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CARM Price Targets Summary
Carisma Therapeutics Inc

Wall Street analysts forecast CARM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CARM is 1.02 USD with a low forecast of 1.01 USD and a high forecast of 1.05 USD.

Lowest
Price Target
1.01 USD
443% Upside
Average
Price Target
1.02 USD
448% Upside
Highest
Price Target
1.05 USD
465% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CARM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CARM Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one CARM stock?

The intrinsic value of one CARM stock under the Base Case scenario is 1.342 USD.

Is CARM stock undervalued or overvalued?

Compared to the current market price of 0.186 USD, Carisma Therapeutics Inc is Undervalued by 86%.

Back to Top